News

/News

News

/News

News

/News

News

/News

News

/News

News

/News

FDA Approves First Drug for Treatment of Parkinson’s Dyskinesia

The US Food and Drug Administration (FDA) has approved amantadine extended-release capsules (Gocovri, Adamas Pharmaceuticals Inc) for treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, the company announced on 8/25/17.

“Gocovri’s approval is an important advancement for […]

By | August 31st, 2017|News|0 Comments

FDA Approves First Drug for cGVHD After Stem Cell Transplant

In a first, the US Food and Drug Administration (FDA) has approved a drug for use in  patients who develop the life-threatening condition of chronic graft-vs-host disease (cGVHD) after having undergone a hematopoietic stem cell transplant (HSCT). The approval was received on August 2nd, 2017. […]

By | August 30th, 2017|News|0 Comments

Artificial Sweeteners Linked to Higher BMI, Cardiometabolic Risk

A new meta-analysis and systematic review finds mixed evidence to support use of artificial sweeteners for weight loss and suggests routine consumption may be associated with long-term weight gain and an increased risk of cardiometabolic disease. Nonnutritive sweeteners, such as aspartame, sucralose and

stevioside, are widely consumed, […]

By | August 29th, 2017|News|0 Comments

FDA Approves Deflazocort (Emflaza®) To Treat Duchenne Muscular Dystrophy (DMD)

On February 9th, 2017 the U.S. Food and Drug Administration (FDA) approved Emflaza® (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness. Emflaza® is a corticosteroid that works […]

By | February 15th, 2017|Blog, News, Pharmacy|0 Comments

Pioglitazone Helps Prevent Secondary Stroke In Patients With Insulin Resistance

PM03Data from a new systematic review and meta-analysis provides evidence the pioglitazone can help prevent secondary stroke in people with abnormal glucose metabolism. Pioglitazone reduced major vascular events after ischemic stroke in a recent randomized controlled trial. The purpose of this study was to conduct a meta-analysis […]

By | January 17th, 2017|Blog, News|0 Comments

FDA approves Darzalex® for patients with previously treated multiple myeloma

pci2On November 16th, 2016 the U.S. Food and Drug Administration (FDA) granted accelerated approval for Darzalex® (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex® is the first monoclonal antibody approved for treating multiple myeloma.

Multiple myeloma is a form of […]

By | December 13th, 2016|Blog, News|0 Comments

Association of Arsenic Exposure and Metabolism With Type 1 and Type 2 Diabetes in Youth

arsenicDiabetes mellitus characterized by hyperglycemia is an increasing worldwide health problem. It is largely classified into insulin-dependent diabetes mellitus (type 1 diabetes) and noninsulin-dependent diabetes mellitus (type 2 diabetes). The type 2 diabetes (T2D) makes up more than 90% of all diabetes cases. Established risk factors for […]

By | December 7th, 2016|Blog, News|0 Comments

FDA Approves Prasterone (Intrarosa®) for Dyspareunia in Postmenopausal Women

pci2 On November 17th, 2016 the U.S. Food and Drug Administration (FDA) approved Intrarosa® (prasterone) manufactured by Quebec-based Endoceutics Inc.to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Intrarosa® is the first FDA […]

By | December 5th, 2016|Blog, News|0 Comments

FDA Strengthens Warnings for All Testosterone Containing Products: Risk of Heart Attack and Stroke Associated With Use

fda-warningsaThe Food and Drug Administration (FDA) has just approved class-wide labeling changes for all prescription testosterone products to inform of possible increased risk of heart attack and stroke with use, the agency announced today1-3.

The medical use of testosterone and anabolic androgenic steroids (AAS) products is FDA-approved as […]

By | November 10th, 2016|Blog, News|0 Comments

FDA Approves Merck’s ZINPLAVA® for Preventing Return of Clostridium Difficile Infections (CDI)

resize_shutterstock_443084233-convertedThe US Food and Drug Administration (FDA) have approved bezlotoxumab injection (ZINPLAVA®, Merck) to reduce the recurrence of Clostridium difficile infection (CDI) in patients aged 18 years or older1-3.

The human monoclonal antibody is specifically indicated for adults who are taking an antibiotic for CDI and are at […]

By | November 3rd, 2016|Blog, News|0 Comments